Daniel Espinoza, MD
Family Medicine · Lithia, FLNPI 1821241431
Payments from drug & device makers
Across 31 payments — averaging $147.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$4K
- Abbott$222
- Exact Sciences$123
- Stryker$69
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$48
- Alnylam Pharmaceuticals Inc.$28
- plus $99 from 5 others
Across 4 payments — averaging $6146.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$25K
What the payments were for
- Speaking & faculty fees$3,00066%
- Travel & lodging$50111%
- Food & beverage$1,06823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 5 | $3,981 |
| Abbott | 11 | $222 |
| Exact Sciences | 6 | $123 |
| Stryker | 1 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Philips North America LLC | 1 | $26 |
| Irhythm Technologies, Inc. | 1 | $25 |
| AbbVie | 1 | $19 |
| Amgen | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$3,905
How this compares
$4,569 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $114,056 |
| OzempicSemaglutide | 92 | $87,654 |
| MounjaroTirzepatide | 41 | $43,563 |
| TrulicityDulaglutide | 19 | $30,134 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $24,248 |
| FarxigaDapagliflozin Propanediol | 23 | $21,965 |
| Repatha SureclickEvolocumab | 33 | $20,756 |
| TradjentaLinagliptin | 12 | $18,557 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $15,595 |
| Repatha PushtronexEvolocumab | 16 | $12,826 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $12,556 |
| Praluent PenAlirocumab | 11 | $7,514 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $4,119 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,498 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,252 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Lithia
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.